Metabolic Engineering of Monoclonal Antibody Carbohydrates for Antibody–Drug Conjugation

2013 ◽  
Vol 24 (10) ◽  
pp. 1650-1655 ◽  
Author(s):  
Nicole M. Okeley ◽  
Brian E. Toki ◽  
Xinqun Zhang ◽  
Scott C. Jeffrey ◽  
Patrick J. Burke ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Metabolic Engineering ◽  
Drug Conjugation ◽  
Antibody Drug

Potential Use of Monoclonal Antibody–Drug Conjugates to Prevent Drug Resistance

1988 ◽  
pp. 371-383 ◽  
Author(s):  
CARL-WILHELM VOGEL ◽  
REINHARD BREDEHORST ◽  
MOUNANANDHAM PANNEERSELVAM ◽  
CAROLE J. SPANGLER
Keyword(s):  
Monoclonal Antibody ◽  
Drug Resistance ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Potential Use ◽  
Antibody Drug

Putative Phospholipase B-Like 2 is Not Responsible for Polysorbate Degradation in Monoclonal Antibody Drug Products

2020 ◽  
Vol 109 (9) ◽  
pp. 2710-2718
Author(s):  
Sisi Zhang ◽  
Hui Xiao ◽  
Michael Goren ◽  
Darya Burakov ◽  
Gang Chen ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Drug Products ◽  
Phospholipase B ◽  
Antibody Drug

scholarly journals Antibody–Drug Conjugates for Cancer Therapy

Molecules ◽  
2020 ◽  
Vol 25 (20) ◽  
pp. 4764
Author(s):  
Umbreen Hafeez ◽  
Sagun Parakh ◽  
Hui K. Gan ◽  
Andrew M. Scott
Keyword(s):  
Monoclonal Antibody ◽  
Molecular Imaging ◽  
Cancer Therapy ◽  
Normal Tissue ◽  
Clinical Development ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Novel Drugs ◽  
Antibody Drug

Antibody–drug conjugates (ADCs) are novel drugs that exploit the specificity of a monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the delivery of a potent cytotoxic payload. ADCs provide a unique opportunity to deliver drugs to tumor cells while minimizing toxicity to normal tissue, achieving wider therapeutic windows and enhanced pharmacokinetic/pharmacodynamic properties. To date, nine ADCs have been approved by the FDA and more than 80 ADCs are under clinical development worldwide. In this paper, we provide an overview of the biology and chemistry of each component of ADC design. We briefly discuss the clinical experience with approved ADCs and the various pathways involved in ADC resistance. We conclude with perspectives about the future development of the next generations of ADCs, including the role of molecular imaging in drug development.

scholarly journals Author Correction: Identification, characterization and control of a sequence variant in monoclonal antibody drug product: a case study

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Anushikha Thakur ◽  
Rekha Nagpal ◽  
Avik Kumar Ghosh ◽  
Deepak Gadamshetty ◽  
Sirisha Nagapattinam ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Drug Product ◽  
Sequence Variant ◽  
And Control ◽  
Antibody Drug

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Effect of cell culture medium components on color of formulated monoclonal antibody drug substance

2013 ◽  
Vol 29 (5) ◽  
pp. 1270-1277 ◽  
Author(s):  
Natarajan Vijayasankaran ◽  
Sharat Varma ◽  
Yi Yang ◽  
Melissa Mun ◽  
Silvana Arevalo ◽  
...  
Keyword(s):  
Cell Culture ◽  
Monoclonal Antibody ◽  
Culture Medium ◽  
Drug Substance ◽  
Cell Culture Medium ◽  
Medium Components ◽  
Antibody Drug
Sign in / Sign up

Export Citation Format

Share Document